On May 23, 2024, Medtronic plc (NYSE: MDT) announced its financial results for the fourth quarter and full year of fiscal year 2024 (FY24).
Glorious Achievements, Retaining the Top Position Once Again
According to the disclosed report,Medtronic's fourth-quarter revenue reached $8.6 billion, achieving a 0.5% growth, with an organic growth rate of 5.4%.The diluted earnings per share (EPS) for the quarter was $0.49 according to Generally Accepted Accounting Principles (GAAP), and the non-GAAP diluted earnings per share was $1.46.According to foreign mediaHairButyl202Top 100 Global Medical Device Companies Over the Past 3 Years,Medtronic, Johnson & Johnson, and Siemens Healthineers Remain Top Three in RevenueStrong.According to the report, Medtronic's total revenue for the fiscal year 2024 reached$32.4 billion, year-on-year growth3.6%, where the organic growth rate is5.2%, andJohnson & JohnsonAndSiemensThe annual revenue of the medical device sector is respectively$30.4 billionAnd$23.4 billion。In contrastMedtronic once again ranked first, retaining the top position.- Profit increased by 12% year-on-year
Medtronic's Diluted Earnings Per Share According to GAAP in FY2024$2.76, non-GAAP diluted earnings per shareThe benefit reached $5.20. In terms of operating cash flow, Medtronic achieved a performance of $6.8 billion in the fiscal year 2024, representing a year-on-year increase of 12%. Additionally, free cash flow reached $5.2 billion, marking a year-on-year growth of 14%. These figures all indicate Medtronic's robust financial performance.- Multiple Products Gain International Approval
The Evolut™ FX+ TAVR System and Inceptiv™ Closed-Loop Spinal Cord Stimulator have received approval from the U.S. Food and Drug Administration (FDA). The Symplicity Spyral™ Renal Denervation System has received approval from the National Medical Products Administration (NMPA) in China. Additionally, the Affera Sphere-9™ Ablation Catheter and Simplera Sync™ CGM have been submitted to the FDA for approval.
Medtronic Chairman and CEO Jeff Martha stated that the company will continue to advance its technologies and strategies in a financially prudent manner, maintaining a strong balance sheet to bring transformative product ecosystems to market and fund their commercialization. The company has multiple goals and aims to achieve breakthrough growth by 2025 and beyond.
- Cardiovascular Business Leads the Overall Growth
Cardiovascular Combination, Neuroscience Product Portfolio,Medical Surgical ProductsCombinationThe diabetes segment also achieved growth at different levels. In particular, the Structural Heart and Aortic (SHA) division within the cardiovascular portfolio achieved high single-digit growth, while the Coronary and Peripheral Vascular (CPV) division achieved mid-single-digit growth.
Looking ahead to fiscal year 2025, Medtronic expects organic revenue growth to be in4%To5%between. The company also expects non-GAAP diluted earnings per share for the fiscal year 2025 to be in$5.40To$5.50Between.In addition, Medtronic announced an increase in its cash dividend for the first quarter of fiscal year 2025 to per share.$0.70, with annual dividends reaching$2.80 per share，Marking the amount of dividend paymentIncreased for the 47th consecutive yearThe company has a strong track record of returning capital to shareholders, including $5.5 billion returned in fiscal year 2024. Medtronic remains committed to returning at least 50% of its free cash flow to shareholders, primarily through dividends and, to a lesser extent, through share repurchases.Thermal Ablation, Medtronic Breaks the Ice and Revives
As a highly anticipated product area for Medtronic, its cardiovascular portfolio includes the Cardiac Rhythm and Heart Failure (CRHF), Structural Heart and Aortic (SHA), and Coronary and Peripheral Vascular (CPV) divisions.In FY2024, the portfolio achieved revenue of $11.831 billion, representing a year-over-year increase of 2.7%, with organic growth reaching 5.0%.In the CRHF division, fourth-quarter performance benefited from high single-digit growth in cardiac pacing therapies, particularly the Micra™ Transcatheter Pacing System, which grew over 20%. Cardiac ablation solutions also achieved mid-single-digit growth, with strong growth in pulsed field ablation (PFA) effectively offsetting the decline in cryoablation.
(Image captured from the official source)In the PFA field, Medtronic has gained a competitive edge with its innovative products and technologies, represented byPulseSelect SystemTreatment is performed using pulsed electric fields, with bipolar, biphasic pulsed electric fields delivered through a circular multi-electrode array catheter. The system consists of five components, including a steerable multi-electrode ring ablation catheter, PFA generator, ECG-Gated, Tableside control, and a 10Fr bidirectional sheath. Its ablation catheter features a proprietary bidirectional waveform and a unique internal wire design, allowing forWithin approximately 30 secondsIsolation of all pulmonary veins, an effect that has been confirmed in the large-scale clinical study PULSED AF.In the global electrophysiology market,Medtronic, Johnson & Johnson, Abbott, Boston ScientificThe competition among leading manufacturers is fierce, and the market share of these three companiesMore than 85%。With the acceleration of population aging, the number of patients with atrial fibrillation in China is expected to continue increasing, and the market size for catheter ablation will keep expanding. As a new generation ablation technology, pulsed field ablation has broad market development potential.
Overall, Medtronic holds a significant market position and technological advantage in the PFA field, with its products and services playing an important role in the electrophysiology market. With continuous technological advancements and further market development, Medtronic's prospects in this field are very optimistic.Fully Build "Iron Cavalry", Marching into Surgical Robotics
In addition to pulsed ablation, Medtronic has significantly increased its focus on surgical robots in recent years. Particularly inHugoAndMAZOR XIn the development and marketing of products such as. It is reported that Medtronic has begun enrolling patients for two new indication studies of the Hugo™ robotic-assisted surgery system:HerniaAndGynecology. And the system has been installed in 25 countries, with over 100 independent scientific publications.(Image captured from the official source)
Medtronic's Executive Vice President of Medical Surgical Business, Mike Marinaro, stated that the company plans to expand its operations across multiple indications, launching a series of products for each indication to increase market share. The Enable Hernia Repair U.S. clinical trial has begun, evaluating the safety and performance of Hugo RAS. Medtronic has also initiated a prospective clinical study in gynecological surgery to support its submission plan to the FDA.Hugo RAS System is a modular multi-quadrant platform designed for various surgical procedures, featuring wristed instruments, 3D visualization, and surgical video capture options in Touch Surgery Enterprise. Medtronic designed the Hugo RAS to provide minimally invasive care to more patients worldwide.The surgical robot market is continuously evolving, with multiple medical technology companies entering the space, hoping to compete with companies like Intuitive Surgical. In the field of orthopedics,StrykerLaunchedMako Surgical Robot，ZimmerBiometLaunchedROSA Surgical Robot. In addition, surgical robotic technologies for soft tissue applications and endoscopic procedures are also continuously evolving, such asJohnson & Johnson Medical TechnologiesAcquiredAuris Health and Its Surgical Robot，CMR SurgicalTheVersius RobotThe system spans more than 130 types of surgical procedures.Medtronic has significantly increased its focus and investment in the surgical robotics field, particularly in the development and market promotion of products like Hugo and MAZOR X. The company is expanding its global presence while pursuing localized growth in the Chinese market, demonstrating its long-term commitment and strategic planning in this area.In summary, Medtronic Group performed outstandingly in the 2024 fiscal year, achieving steady growth financially while also making significant accomplishments in product innovation, market expansion, and shareholder returns. Looking ahead, with the company’s continuous global market expansion and the ongoing launch of innovative products, Medtronic is well-positioned to maintain its status as an industry leader and achieve even more impressive performance in the 2025 fiscal year and beyond.▲ Source of the article: Medical Device Innovation Network▲Please indicate the source above when reprintingDisclaimer: This article is intended solely for the purpose of information transmission and is for reference only. It does not constitute any advice on investment or treatment; please exercise caution. If it involves issues related to the content, copyright, or other aspects of the work, to protect the rights and interests of both parties, please contact us and we will handle it immediately. If any platform reprints this article, it must take responsibility for the content itself; the Medical Device Innovation Network is not responsible for any secondary dissemination caused by the reprint.
